Clinical Trial Update: Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for ibrutinib in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous Lymphoma
• Intraocular Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Primary Central Nervous Lymphoma, Intraocular Lymphoma | Phase 2 | Status: COMPLETED